HPV Testing in Primary Cervical Screening: A Systematic Review and Meta-Analysis

Journal of Obstetrics and Gynaecology Canada

Volumn 34, Issue 5, 2012, Pages 443-452

  Murphy, Joan ^a   Kennedy, Erin B ^b   Dunn, Sheila ^c   McLachlin, C Meg ^d   Kee Fung, Michael Fung ^e   Gzik, Danusia ^f   Shier, Michael ^g   Paszat, Lawrence ^h  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f North Simcoe Muskoka Local Health Integration Network   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^h INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Cancer prevention; Cervical cancer screening; Cervical cytology; HPV testing

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLPOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; META ANALYSIS; PATIENT REFERRAL; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR INVASION; UTERINE CERVIX CARCINOMA IN SITU; EARLY DIAGNOSIS; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; REVIEW; UTERINE CERVIX TUMOR; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84867601658     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)35241-0     Document Type: Article

References (26)

1. Sasieni P., Castanon A., Cuzick J. What is the right age for cervical cancer screening?. Women's Health 2010, 6:1-4.
2. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian cancer statistics 2011 2011, Canadian Cancer Society, Toronto, ON.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
4. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
5. Franco E.L. Is the UK ready to embrace HPV testing?. Lancet Oncol 2009, 10:643-644.
6. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(10):29-41. Suppl.
7. Anttila A., Kotaniemi-Talonen L., Leinonen M., Hakama M., Laurila P., Tarkkanen J., et al. Rate of cervical cancer, severe intraepithelial neoplasia,and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010, 340:1804.
8. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257.
9. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
10. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597.
11. Kitchener H.C., Almonte M., Thomson C., Wheeler P., Sargent A., Stoykova B., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009, 10:672-682.
12. Mayrand M., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-1588.
13. Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
14. Whiting P., Rutjes A., Reitsma J., Bossuyt P., Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Method 2003, 3:25.
15. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] 2011, Available at: Accessed March 12, 2011. http://www.cochrane-handbook.org.
16. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009, 101:88-99.
17. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008, 100(7):492-501.
18. Davies P., Arbyn M., Dillner J., Kitchener H.C., Meijer C.J., Ronco G., et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 2006, 118:791-796.
19. Whitlock E.P., Vesco K.K., Eder M., Lin J.S., Senger C.A., Burda B.U. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155:687-697.
20. Arbyn M., Cuzick J. International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention [Review]. Cancer Lett 2009, 278:1-2.
21. Ronco G., Meijer C.J., Cuzick J., Giorgi-Rossi P., Peto J., Segnan N., et al. Human papillomavirus testing to screen for cervical cancer. Ann Intern Med [online] November 11, 2011 2011, November 11 Available at Accessed February 27, 2012. http://www.annals.org/content/155/10/687.figures-only/reply#annintmed_el_127598.
22. Leinonen M., Nieminen P., Kotaniemi-Talonen L., Malila N., Tarkkanen J., Laurila P., et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009, 101:1612-1623.
23. Bartholomew D.A. Human papillomavirus infection in adolescents:a rational approach. Adolesc Med Clin 2004, 15:569-595.
24. Dillner J., Rebolj M., Birembaut P., Petry K.U., Szarewski A., Munk C., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:1754.
25. McLachlin C.M., Mai V., Murphy J., Fung-Kee-Fung M., Chambers A., Oliver T.K., et al. Cervical Screening Guidelines Development Committee of the Ontario Cervical Screening Program; Gynecology Cancer Disease Site Group of Cancer Care Ontario. Ontario cervical cancer screening clinical practice guidelines. J Obstet Gynaecol Can 2007, 29:344-353.
26. Kitchener H.C., Gilham C., Sargent A., Bailey A., Albrow R., Roberts C., et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011, 47:864-871.